Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
Jacob D. Soumerai(Harvard University), Deborah M. Stephens(University of North Carolina at Chapel Hill), Alan P Skarbnik(Novant Health), Harsh Shah(University of Utah), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Patrick K. Reville(The University of Texas MD Anderson Cancer Center), Ryan Jacobs(Levine Cancer Institute), Douglas E. Gladstone(Northwell Health), Inhye E. Ahn(Dana-Farber Cancer Institute), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Andrew Lipsky(NOAA National Marine Fisheries Service), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Daniel A. Ermann(University of Utah), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Jacqueline C. Barrientos(Mount Sinai Medical Center), Krish Patel, Marc Hoffmann(The University of Kansas Cancer Center)
Cited by 19
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k